This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain – Harbor ETF Trust Harbor Disruptive Innovation ETF (ARCA:INNO)
Medical Marijuana Program Connection
APRIL 23, 2024
Food and Drug Administration (FDA), for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. Innocan Pharma Corporation INNO IP INNPF announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. With the move, the company initiated the regulatory process with the FDA.
40 
Let's personalize your content